Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06027229 | Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations | PHASE2 | COMPLETED | 21 | — | — | Nov 20, 2023 | Sep 9, 2024 | Oct 20, 2025 | 1 | United States |
Antibody concentrations 1 month after the recombinant vaccine booster (V2) in patients with IBD and solid organ transplant recipients compared to their baseline visit (V1).
| Arm | Type | Description |
|---|---|---|
| Participants who have had Solid Organ Transplants | EXPERIMENTAL | Male and females aged 18 to 85 who are solid organ transplant recipients and receive the study intervention. |
| Participants with IBD | EXPERIMENTAL | Male and females aged 18 to 85 who have IBD and receive the study intervention. |
| Name | Type | Description |
|---|---|---|
| NVX-CoV2372 | BIOLOGICAL | Novavax COVID-19 Vaccine Booster for Omicron XBB.1.5 |
Inclusion Criteria: • Patient has a history of ulcerative colitis (UC), Crohn's disease, pouchitis, or indeterminate colitis diagnosed by standard clinical, radiographic, endoscopic, and histopathologic criteria. And / or patient is a solid organ transplant recipient (e.g. lung, kidney, liver) * ...